NCT05581004 2026-02-17A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsGenentech, Inc.Phase 1 Recruiting450 enrolled
NCT03228667 2026-01-14QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsImmunityBio, Inc.Phase 2 Active not recruiting40 enrolled
NCT03614949 2025-12-19SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical CancerH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Active not recruiting21 enrolled
NCT04157985 2025-12-11Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsUniversity of PittsburghPhase 3 Completed161 enrolled
NCT03738228 2025-11-12Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical CancerNational Cancer Institute (NCI)Phase 1 Completed40 enrolled 17 charts